Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174864
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Martínez Santana, Virginia | - |
dc.contributor.author | Rodríguez Murphy, Esther | - |
dc.contributor.author | Smithson Amat, Alejandro | - |
dc.contributor.author | Miserachs Aranda, Nuria | - |
dc.contributor.author | Río-Gil, Ruben del | - |
dc.contributor.author | Torre Lloverás, Inmaculada | - |
dc.date.accessioned | 2021-03-10T13:04:54Z | - |
dc.date.available | 2021-03-10T13:04:54Z | - |
dc.date.issued | 2017-05-20 | - |
dc.identifier.issn | 2047-9956 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174864 | - |
dc.description.abstract | Background: The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown. Case report: We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis. Conclusion: This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted. | - |
dc.format.extent | 4 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1136/ejhpharm-2017-001212 | - |
dc.relation.ispartof | European Journal Of Hospital Pharmacy-Science And Practice, 2018, vol. 25, num. 1, p. 53-56 | - |
dc.relation.uri | https://doi.org/10.1136/ejhpharm-2017-001212 | - |
dc.rights | (c) European Association of Hospital Pharmacists, 2018 | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.classification | Malalties autoimmunitàries | - |
dc.subject.classification | Interaccions dels medicaments | - |
dc.subject.other | Hepatitis C | - |
dc.subject.other | Autoimmune diseases | - |
dc.subject.other | Drug interactions | - |
dc.title | Efficacy and safety of direct-acting antiviral agents when combined with secukinumab | - |
dc.type | info:eu-repo/semantics/article | - |
dc.identifier.idgrec | 708019 | - |
dc.date.updated | 2021-03-10T13:04:54Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31156986 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
708019.pdf | 391.84 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.